Orchid Pharma Limited — Others, 11-11-2024: Monitoring Agency Report

Orchid Pharma Limited's Monitoring Agency Report for the second quarter of FY 2024-25 indicates that the proceeds from its recent Qualified Institutions Placement (QIP) of ₹400 crore are being utilized effectively, with no deviations from the stated objectives. As of September 30, 2024, ₹150.24 crore has been utilized, while ₹204.30 crore remains unutilized. Delays in the Jammu manufacturing facility and the Alathur API upgrades have caused some of the funds to remain idle, but management assures that major land acquisition is complete, and projects are now fast-tracking.

This update suggests a positive outlook for the company's project execution, though operational delays may pose potential risks. Investors might take comfort in the effective management of proceeds and the eventual realization of planned expansions.